Register for our free email digests:
Kite Pharma Inc.
Latest From Kite Pharma Inc.
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
With overseas revenues rising sharply in the first half of 2017, Fosun Pharma expects to build on its global investment strategy at a fast pace, striking more deals to acquire products and companies from developed markets.
Gritstone closed a Series B venture capital financing to advance its immunotherapy based on cancer patients' own neoantigens into clinical testing and to explore a new shared antigen platform.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Kite Pharma Inc.
- Senior Management
Arie Belldegrun, MD, Pres. & CEO
Paul Jenkinson, CFO
David Chang, MD, PhD, EVP, R&D & CMO
Cynthia M Butitta, COO
Shawn Tomasello, Chief Commercial Officer
- Contact Info
Kite Pharma Inc.
Phone: (310) 824-9999
2225 Colorado Ave.
Santa Monica, CA 90404
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.